Lupus nephritis in Indigenous Australians: a single-centre study.

Area of Science:

• Nephrology
• Immunology
• Public Health

Background:

• Lupus nephritis (LN) presentation and outcomes vary significantly across different global populations.
• Data on LN in non-Caucasian populations in Australia, particularly Indigenous communities, are limited.
• Understanding these variations is crucial for equitable healthcare delivery.

Purpose of the Study:

• To investigate the clinical presentation, histological characteristics, disease progression, and outcomes of lupus nephritis in Aboriginal and Torres Strait Islander individuals.
• To describe the natural history of biopsy-proven lupus nephritis in a specific Indigenous population in Far North Queensland.
• To identify potential disparities in disease severity and treatment response.

Main Methods:

• Retrospective observational study conducted in Queensland, Australia.
• Inclusion of Aboriginal and Torres Strait Islander patients with biopsy-proven lupus nephritis treated between 1990 and 2013.
• Primary outcome measures included renal replacement therapy and overall patient survival.

Main Results:

• Aboriginal and Torres Strait Islander people constituted 40% of all diagnosed LN patients during the study period.
• High incidence of nephrotic range proteinuria (78.5%), impaired kidney function (42.8%), and proliferative LN (81.25%) at presentation.
• Low remission rates (28.5%) and high rates of end-stage kidney disease (28.5%) and mortality (31.25%) were observed despite immunosuppressive therapy.

Conclusions:

• Lupus nephritis in Aboriginal and Torres Strait Islander populations in Far North Queensland presents with severe clinical features.
• Standard immunosuppressive therapies demonstrate unsatisfactory response rates in this cohort.
• Further multi-center prospective studies are essential to elucidate ethnic disparities in LN prognosis and treatment efficacy.